Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 11/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185434 | 0.86 | DRD2 (0.63) | DRD2MEN1KMT2ADRD4ATM | |
| SCHEMBL14207951 | 0.84 | DRD4 (0.67) | DRD2MEN1KMT2ADRD4ATM | |
| SCHEMBL521024 | 0.83 | DRD4 (0.49) | DRD2MEN1KMT2ADRD4MAPK1 | |
| SCHEMBL3436370 | 0.82 | DRD4 (0.59) | DRD2DRD4 | |
| SCHEMBL14412952 | 0.82 | MEN1 (0.71) | DRD2MEN1KMT2ADRD4CHRM4 | |
| SCHEMBL3436049 | 0.80 | CYP2C19 (0.44) | MEN1KMT2ADRD4 | |
| SCHEMBL8304330 | 0.80 | DRD2 (0.78) | DRD2MEN1KMT2ADRD4ATM | |
| SCHEMBL20419231 | 0.80 | MEN1 (0.65) | DRD2MEN1KMT2ADRD4CHRM4 | |
| SCHEMBL27597066 | 0.79 | CYP2C9 (0.50) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2078695 | 0.79 | CYP2C19 (0.43) | MEN1KMT2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | DRD2 3505/4885MEN1 2838/4885KMT2A 752/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | DRD2 3495/4885MEN1 3641/4885KMT2A 2977/4885 |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | DRD2 3508/4885MEN1 4589/4885KMT2A 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.